AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
AstraZeneca's price to sales ratio was 8.7× on Oct 19, 2026, against 9.5× a year earlier. Over the last 5 years it ranged from 5.4× to 12.1×, with a median of 9.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 8.7× | −1.9 |
| 2025 | Dec 31, 2025 | 10.6× | +1.7 |
| 2024 | Dec 31, 2024 | 8.9× | −0.5 |
| 2023 | Dec 29, 2023 | 9.5× | −0.9 |
| 2022 | Dec 30, 2022 | 10.3× | +4.8 |
| 2017 | Jan 31, 2017 | 5.6× | −0.0 |
| 2016 | Dec 30, 2016 | 5.6× | – |
See a number that looks wrong?